FDA okays Israeli drug for coronavirus treatment trials

NeuroRx, a US-Israeli pharmaceutical company, and Relief Therapeutics, a Swiss drug development company, announced Sunday they received the go-ahead from the Food and Drug Administration (FDA) for phase two trials of a drug that could take on a deadly condition associated with COVID-19.

The companies revealed that the FDA issued a “study may proceed” letter — which does not amount to a fully-fledged drug approval — for the substance to be tried on COVID-19 patients.

The drug in question, Aviptadil, is a synthetic form of a neuropeptide hormone that works to enable communications between neurons in the human nervous system.

Read More: I-24